Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Thomas, Strack"'
Autor:
Chenyu Lin, Ahmed Galal, David Rizzieri, Sant Chawla, Seung T. Lee, Angela Georgy, Kristina Dabovic, Thomas Strack, Matthew McKinney
Publikováno v:
Cancer Investigation. 41:253-262
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5883fda5bc97fc580614d1cdf6e9168d
https://doi.org/10.1080/07357907.2022.2162073
https://doi.org/10.1080/07357907.2022.2162073
Autor:
Daniel O. Persky, Jack P. Higgins, Banmeet S. Anand, Eric T. Williams, Thomas Strack, Kristina Dabovic, Christine Burnett, Steven I. Park, Vasile Musteata, Paul A. Hamlin
Supplementary Table 1. Additional Study Eligibility Criteria. Supplementary Table 2. Pharmacokinetic Serum Sample Collection. Supplementary Table 3. Summary of Adverse Events and Discontinuations. Supplementary Table 4. Summary of Serum MT-3724 PK Pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9e8eb3a182d2381d2a0f99c3e33c520
https://doi.org/10.1158/2767-9764.22544535.v1
https://doi.org/10.1158/2767-9764.22544535.v1
Autor:
Daniel O. Persky, Jack P. Higgins, Banmeet S. Anand, Eric T. Williams, Thomas Strack, Kristina Dabovic, Christine Burnett, Steven I. Park, Vasile Musteata, Paul A. Hamlin
MT-3724, a novel engineered toxin body comprised of an anti-CD20 single-chain variable fragment genetically fused to Shiga-like Toxin A subunit, is capable of binding to and internalizing against CD20, inducing cell killing via permanent ribosomal in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17cc7aa635f71b1ffab59651a623b580
https://doi.org/10.1158/2767-9764.c.6550680.v1
https://doi.org/10.1158/2767-9764.c.6550680.v1
Autor:
Paul A. Hamlin, Vasile Musteata, Steven I. Park, Christine Burnett, Kristina Dabovic, Thomas Strack, Eric T. Williams, Banmeet S. Anand, Jack P. Higgins, Daniel O. Persky
Publikováno v:
Cancer Research Communications. 2:307-315
MT-3724, a novel engineered toxin body comprised of an anti-CD20 single-chain variable fragment genetically fused to Shiga-like Toxin A subunit, is capable of binding to and internalizing against CD20, inducing cell killing via permanent ribosomal in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e31f7af1ec515d84ed32748d3be371e
https://doi.org/10.1158/2767-9764.crc-22-0056
https://doi.org/10.1158/2767-9764.crc-22-0056
Autor:
Brian A. Van Tine, Monica Mita, Minal A. Barve, Erika P. Hamilton, Andrew J. Brenner, Frances Valdes, Daniel Ahn, Joleen Hubbard, Jason Starr, Angela Georgy, Joshua Pelham, Banmeet S. Anand, Thomas Strack, Andrés Machado Sandri, Zev A. Wainberg
Publikováno v:
Cancer Research. 82:P2-13
Background: Engineered toxin bodies (ETBs) are composed of a de-immunized Shiga-like Toxin A subunit genetically fused to an antibody-like binding domain. ETBs can force receptor internalization, induce potent cell-kill via enzymatic and permanent in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a9db99f3de1dd19cc31e0a6f2544d7b7
https://doi.org/10.1158/1538-7445.sabcs21-p2-13-45
https://doi.org/10.1158/1538-7445.sabcs21-p2-13-45
Publikováno v:
Diabetes, Metabolic Syndrome and Obesity, Vol 2009, Iss default, Pp 1-10 (2009)
Thomas Strack1, Luc Martinez2, Stefano Del Prato3, Larry Blonde4, Burkhard Göke5, Vincent Woo6, Ann Millward7, Ramon Gomis8, Bill Canovatchel1, David Lawrence1, Nick Freemantle9 on behalf of the EXPERIENCE Trial Team1Pfizer Inc., New York, NY, USA;
Externí odkaz:
https://doaj.org/article/4ba2d7f98161403896fb0539e2d789f8
Autor:
Brian Andrew Van Tine, Joleen M. Hubbard, Monica M. Mita, Minal A. Barve, Erika P. Hamilton, Andrew J. Brenner, Frances Valdes, Daniel H. Ahn, Jason S. Starr, Joshua Pelham, Thomas Strack, Amy Yuet, Diana Yurewicz, Taunya J. Smith, Andres Machado, William Jeffery Edenfield, Aki Morikawa, Meena Okera, Nihal E. Abdulla, Zev A. Wainberg
Publikováno v:
Journal of Clinical Oncology. 40:2583-2583
2583 Background: MT-5111 is a 55kD engineered toxin body (ETB) targeting HER2 in solid tumors that binds to an epitope distinct from trastuzumab and pertuzumab, offering potential combination strategies with other HER2-targeting agents. MT-5111 may d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4c63840b7f1e121903b30cb2093210e0
https://doi.org/10.1200/jco.2022.40.16_suppl.2583
https://doi.org/10.1200/jco.2022.40.16_suppl.2583
Autor:
Joleen M. Hubbard, Brian Andrew Van Tine, Monica M. Mita, Minal A. Barve, Erika P. Hamilton, Andrew J. Brenner, Frances Valdes, Daniel H. Ahn, Jason S. Starr, Susan Lerner, Joshua Pelham, Banmeet S. Anand, Thomas Strack, Andres Machado Sandri, Zev A. Wainberg
Publikováno v:
Journal of Clinical Oncology. 40:297-297
297 Background: MT-5111 is a 55 kD engineered toxin body (ETB) targeting HER2 in solid tumors that binds to an epitope distinct from trastuzumab and pertuzumab, offering potential combination strategies with other HER2-targeting agents. MT-5111 may d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2d4853a61b7eaf60009f0341ff74589d
https://doi.org/10.1200/jco.2022.40.4_suppl.297
https://doi.org/10.1200/jco.2022.40.4_suppl.297
Autor:
Eric T Williams, Frances Valdes, Joshua Pelham, Erika Hamilton, Joleen M. Hubbard, Banmeet Anand, Christine Burnett, Minal A. Barve, Andrés Machado Sandri, Zev A. Wainberg, Andrew Brenner, Brian A. Van Tine, Daniel H. Ahn, Thomas Strack, Monica M. Mita, Jason S. Starr
Publikováno v:
Cancer Research. 81:CT130-CT130
Background: Engineered toxin bodies (ETBs), composed of an engineered Shiga-like Toxin A subunit genetically fused to an antibody-binding domain, can force receptor internalization, induce potent cell-kill via enzymatic and permanent inactivation of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::40bbdb10fe35dc65efeafaac97d4fbe8
https://doi.org/10.1158/1538-7445.am2021-ct130
https://doi.org/10.1158/1538-7445.am2021-ct130
Autor:
Richard B. Noto, Vivien Wong, Stanley J. Goldsmith, Daniel A. Pryma, Tess Lin, Jessica Jensen, Nancy Stambler, Thomas Strack
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 103:213-220
Context No therapies are approved for the treatment of metastatic and/or recurrent pheochromocytoma or paraganglioma (PPGL) in the United States. Objective To determine the maximum tolerated dose (MTD) of high-specific-activity I-131 meta-iodobenzylg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b51ea0f13d644ed9e7b15bf6c142dbc
https://doi.org/10.1210/jc.2017-02030
https://doi.org/10.1210/jc.2017-02030